Article Text

Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
  1. Larissa Mulka,
  2. David Annandale,
  3. Claire Richardson,
  4. Martin Fisher,
  5. Daniel Richardson
  1. Brighton and Sussex University Hospitals NHS Trust
  1. Correspondence to Dr Larissa Mulka, Department of Sexual Health and HIV, Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE, UK; larissa.mulka{at}

Statistics from

Raltegravir is a well-tolerated alternative third agent used in postexposure prophylaxis (PEP).1 ,2 In a single-centre study reviewing reasons for initiation and tolerability of raltegravir-PEP, we identified patients receiving PEP between February 2010 and April 2012. All patients receiving raltegravir-PEP were matched with standard-PEP controls (tenofovir-emtricitabine with lopinavir-ritonavir (LPV/r)). Ethical approval was not required as data was collected for service evaluation.

During this period 509 courses of PEP were prescribed, 33 (6.5%) containing raltegravir. Of the 61 cases analysed 66 (92%) were prescribed PEP following sexual exposure, 54/66 (82%) were male; 47/66 (71%) men who have sex with men. Of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.